Private Placements, Capital Formation,
Restructuring & Recapitalizations



SCOLR Pharma ~ $11,850,500 Common Stock ~ April 2006

SCOLR Pharma, Inc. is a specialty pharmaceutical company that is developing novel prescription and OTC drugs based on the Company’s proprietary CDT drug delivery platform. The Company’s CDT platform for oral drug dosage is simple to manufacture, inexpensive and offers flexible dosage release for hard to formulate drugs. SCOLR is developing the first extended release ibuprofen under an agreement with Wyeth. The Company also has a strategic alliance with Perrigo to manufacture and market certain sustained release nutritional products and is developing extended release versions of pseudoephedrine, raloxifene and ondansetron. Taglich Brothers was pleased to provide this strategically important financing allowing SCOLR to continue the execution of its development activities.

The information contained herein does not constitute a solicitation of any order to buy or sell any securities. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Taglich Brothers, Inc.